HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thomas A Puchalski Selected Research

siltuximab

5/2015Dose selection of siltuximab for multicentric Castleman's disease.
1/2015A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
8/2014Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
4/2014A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
1/2014Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.
7/2013A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
6/2013A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Thomas A Puchalski Research Topics

Disease

12Neoplasms (Cancer)
03/2015 - 09/2002
4Multiple Myeloma
05/2015 - 07/2013
4Neoplasm Metastasis (Metastasis)
03/2015 - 07/2007
3Neutropenia
03/2015 - 07/2013
3Thrombocytopenia (Thrombopenia)
01/2015 - 11/2009
3Fatigue
07/2013 - 04/2004
2Non-Hodgkin Lymphoma (Lymphosarcoma)
05/2015 - 07/2013
2Multi-centric Castleman's Disease
05/2015 - 08/2014
2Stomatitis
03/2015 - 04/2004
2Anemia
03/2015 - 07/2013
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2014 - 04/2008
2Prostatic Neoplasms (Prostate Cancer)
06/2013 - 06/2013
2Vomiting
04/2013 - 04/2004
2Nausea
04/2013 - 04/2004
2Diarrhea
11/2009 - 07/2007
1Circulating Neoplastic Cells
03/2015
1Thrombocytopenia 4
03/2015
1Febrile Neutropenia
03/2015
1Infections
01/2015
1Sepsis (Septicemia)
08/2014
1Anaphylaxis (Anaphylactic Shock)
08/2014
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
08/2014
1Respiratory Tract Infections (Respiratory Tract Infection)
08/2014
1Smoldering Multiple Myeloma
01/2014
1Heart Diseases (Heart Disease)
01/2014
1Monoclonal Gammopathy of Undetermined Significance
01/2014
1Leukopenia
07/2013
1Hypercholesterolemia
07/2013
1Castleman Disease (Castleman's Disease)
07/2013
1Fever (Fevers)
07/2013
1Hypertriglyceridemia
07/2013
1Anorexia
07/2013
1Headache (Headaches)
04/2013
1Carcinogenesis
04/2013
1Pruritus (Itching)
04/2013
1Proteinuria
11/2009
1Hemorrhage
04/2008
1Hypertension (High Blood Pressure)
07/2007
1Dysphonia (Spastic Dysphonia)
07/2007
1Hyperglycemia
04/2004
1Colorectal Neoplasms (Colorectal Cancer)
02/2004
1Sarcoma (Soft Tissue Sarcoma)
10/2002

Drug/Important Bio-Agent (IBA)

9Monoclonal AntibodiesIBA
03/2015 - 04/2013
7siltuximabIBA
05/2015 - 06/2013
4LigandsIBA
03/2015 - 04/2013
4Pharmaceutical PreparationsIBA
03/2015 - 10/2002
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2009 - 09/2002
3carlumabIBA
03/2015 - 04/2013
3CC ChemokinesIBA
03/2015 - 04/2013
3Docetaxel (Taxotere)FDA Link
03/2015 - 06/2013
3cediranib (AZD2171)IBA
11/2009 - 07/2007
2AntibodiesIBA
03/2015 - 09/2002
2InterleukinsIBA
08/2014 - 04/2014
2Interleukin-6 (Interleukin 6)IBA
08/2014 - 06/2013
2Paclitaxel (Taxol)FDA LinkGeneric
04/2008 - 09/2003
2Fluorouracil (Carac)FDA LinkGeneric
04/2004 - 02/2004
11-dodecylpyridoxal (PLD)IBA
03/2015
1GemcitabineFDA Link
03/2015
1Dihydrotachysterol (AT 10)IBA
03/2015
1Bortezomib (Velcade)FDA Link
01/2015
1ErbB Receptors (EGF Receptor)IBA
04/2014
1ChemokinesIBA
10/2013
1Hemoglobins (Hemoglobin)IBA
07/2013
1Phosphotransferases (Kinase)IBA
04/2008
1Carboplatin (JM8)FDA LinkGeneric
04/2008
1Tyrosine (L-Tyrosine)FDA Link
04/2008
1midostaurinIBA
04/2004
1StaurosporineIBA
04/2004
1Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA
02/2004
1Thymidylate SynthaseIBA
02/2004
1Leucovorin (Folinic Acid)FDA Link
02/2004
1liposomal doxorubicin (Doxil)FDA Link
09/2003
1PlatinumIBA
09/2003
1TrabectedinIBA
10/2002
1Antineoplastic Agents (Antineoplastics)IBA
10/2002
1EndostatinsIBA
09/2002
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
09/2002

Therapy/Procedure

3Drug Therapy (Chemotherapy)
03/2015 - 02/2004
3Therapeutics
11/2009 - 09/2003
2Castration
06/2013 - 06/2013
2Intravenous Infusions
04/2013 - 10/2002